Published in J Clin Lipidol on April 07, 2015
Prevalence of Nontraumatic Osteonecrosis of the Femoral Head and its Associated Risk Factors in the Chinese Population: Results from a Nationally Representative Survey. Chin Med J (Engl) (2015) 1.01
Hierarchical modelling of blood lipids' profile and 10-year (2002-2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study. Lipids Health Dis (2015) 0.82
Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile? Cardiovasc Diabetol (2016) 0.81
A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. Adv Ther (2016) 0.81
Egg Consumption and Human Cardio-Metabolic Health in People with and without Diabetes. Nutrients (2015) 0.80
PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. Clin Cardiol (2017) 0.80
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. Coron Artery Dis (2016) 0.77
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. J Clin Pharmacol (2016) 0.76
The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids Health Dis (2016) 0.76
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation (2016) 0.76
Saturated Fatty Acids and Cardiovascular Disease: Replacements for Saturated Fat to Reduce Cardiovascular Risk. Healthcare (Basel) (2017) 0.76
Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk. BMJ Open Diabetes Res Care (2015) 0.75
Effect of phytosterols and inulin-enriched soymilk on LDL-cholesterol in Thai subjects: a double-blinded randomized controlled trial. Lipids Health Dis (2015) 0.75
Patient-centered Blood Pressure: Thresholds, Targets, and Tools in Diabetes. Indian J Endocrinol Metab (2017) 0.75
Consensus statement on the management of dyslipidemia in Indian subjects: Our perspective. Indian Heart J (2016) 0.75
Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review. Blood Transfus (2015) 0.75
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Cardiovasc Drugs Ther (2016) 0.75
Relationship between non-high-density lipoprotein cholesterol and carotid atherosclerosis in normotensive and euglycemic Chinese middle-aged and elderly adults. Lipids Health Dis (2017) 0.75
Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med (2016) 0.75
Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines. Circulation (2016) 0.75
Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. J Clin Lipidol (2016) 0.75
Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©. Patient (2016) 0.75
Corn oil intake favorably impacts lipoprotein cholesterol, apolipoprotein and lipoprotein particle levels compared with extra-virgin olive oil. Eur J Clin Nutr (2016) 0.75
Association between serum non-high-density lipoprotein cholesterol and cognitive impairment in patients with acute ischemic stroke. BMC Neurol (2016) 0.75
Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. Sci Rep (2017) 0.75
Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management. Arq Bras Cardiol (2017) 0.75
The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk. Arq Bras Cardiol (2017) 0.75
The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. Curr Atheroscler Rep (2017) 0.75
Elevated levels of very low-density lipoprotein cholesterol independently associated with in-stent restenosis in diabetic patients after drug-eluting stent implantation. Chin Med J (Engl) (2017) 0.75
National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol (2014) 2.39
National Lipid Association Annual Summary of Clinical Lipidology 2015. J Clin Lipidol (2014) 1.01
An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol (2014) 0.91
Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia. Curr Med Res Opin (2008) 0.87
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol (2015) 0.87
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) (2013) 0.86
Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). J Clin Lipidol (2014) 0.81
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol (2016) 0.79
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis (2016) 0.78
Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. Int J Gen Med (2014) 0.76
National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol (2016) 0.76
JCL roundtable: PCSK9 inhibitors in clinical practice. J Clin Lipidol (2015) 0.75
Clinical lipidology: A subspecialty whose time has come. J Clin Lipidol (2015) 0.75